ImClone files delayed Erbitux cancer treatment application to U.S. regulators

NEW YORK (AP) - ImClone Systems Inc. said Tuesday that it submitted an application to U.S. regulators to expand the approval of its Erbitux cancer treatment to include head and neck cancer, meeting a revised filing schedule....More